IQVIA Holdings Inc. (NYSE:IQV) Short Interest Update

IQVIA Holdings Inc. (NYSE:IQV) was the recipient of a large growth in short interest in August. As of August 15th, there was short interest totalling 2,400,000 shares, a growth of 7.6% from the July 31st total of 2,230,000 shares. Approximately 1.3% of the shares of the stock are short sold. Based on an average daily volume of 990,200 shares, the short-interest ratio is currently 2.4 days.

IQVIA Price Performance

NYSE:IQV opened at $222.63 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 2.16. The firm has a fifty day simple moving average of $220.34 and a 200 day simple moving average of $208.18. IQVIA has a 1-year low of $165.75 and a 1-year high of $241.86. The stock has a market capitalization of $40.77 billion, a PE ratio of 38.32, a P/E/G ratio of 2.25 and a beta of 1.37.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, August 1st. The medical research company reported $2.22 EPS for the quarter, topping analysts’ consensus estimates of $2.09 by $0.13. IQVIA had a net margin of 7.47% and a return on equity of 30.14%. The firm had revenue of $3.73 billion during the quarter, compared to analysts’ expectations of $3.70 billion. On average, research analysts expect that IQVIA will post 9.21 EPS for the current fiscal year.

Analyst Ratings Changes

IQV has been the subject of a number of recent research reports. Barclays lifted their price objective on shares of IQVIA from $230.00 to $250.00 in a research note on Tuesday, June 27th. Citigroup lifted their price objective on shares of IQVIA from $200.00 to $225.00 and gave the company a “neutral” rating in a report on Wednesday, August 2nd. Morgan Stanley increased their price target on IQVIA from $220.00 to $240.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 2nd. Truist Financial boosted their price target on shares of IQVIA from $244.00 to $260.00 and gave the stock a “buy” rating in a research note on Tuesday, July 18th. Finally, Stifel Nicolaus increased their target price on shares of IQVIA from $255.00 to $281.00 and gave the company a “buy” rating in a report on Wednesday, August 2nd. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $251.38.

Insider Activity at IQVIA

In other IQVIA news, insider Kevin C. Knightly sold 5,820 shares of IQVIA stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $201.89, for a total value of $1,174,999.80. Following the sale, the insider now owns 1,973 shares of the company’s stock, valued at approximately $398,328.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of IQV. Bank Julius Baer & Co. Ltd Zurich increased its stake in shares of IQVIA by 59,295.3% in the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 57,650,851 shares of the medical research company’s stock valued at $12,958,182,000 after buying an additional 57,553,788 shares during the period. State Street Corp raised its stake in shares of IQVIA by 2.5% during the 2nd quarter. State Street Corp now owns 8,451,571 shares of the medical research company’s stock worth $1,899,660,000 after purchasing an additional 207,148 shares during the period. Alliancebernstein L.P. raised its stake in IQVIA by 19.1% in the 2nd quarter. Alliancebernstein L.P. now owns 5,942,761 shares of the medical research company’s stock valued at $1,335,754,000 after acquiring an additional 952,850 shares during the period. FMR LLC grew its holdings in IQVIA by 24.7% during the 1st quarter. FMR LLC now owns 5,620,968 shares of the medical research company’s stock valued at $1,117,954,000 after buying an additional 1,111,803 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in IQVIA by 2.7% in the 2nd quarter. Geode Capital Management LLC now owns 3,907,023 shares of the medical research company’s stock worth $875,861,000 after buying an additional 102,862 shares during the last quarter. Institutional investors and hedge funds own 86.82% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.